Boston Scientific Corporation (NYSE:BSX) is among the 10 Most Oversold S&P 500 Stocks So Far in 2026. On May 29, Wolfe Research downgraded the stock from Outperform to Peer Perform.
This marks the end of the firm’s bullish outlook on the stock for four years, with the adjustment coming after the company said sales growth of its Watchman implant, which reduces the risk of stroke, was slowing.
Wolfe Research now anticipates 7% organic growth for Boston Scientific Corporation in 2027, according to TipRanks, which would put the share price in the early $50s, roughly the same level the stock is trading at currently.
Following the Watchman update, TD Cowen also lowered its price target on the stock to $61 from $80, but maintained a Buy rating.
Despite recent analyst revisions, BSX remains a Strong Buy based on 27 analysts’ recommendations and has an average share price upside of 70% as of the close on May 29.
Boston Scientific Corporation is a global medical technology company that manufactures and markets medical devices that are used in several interventional medical specialties.
READ NEXT: 10 Best Performing Defense Stocks So Far in 2026 and 10 Stocks That Will Make You Rich Over the Next Decade.
